Related Experiment Video
Updated: Apr 28, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.3K
Noninsulin Medications for Type 2 Diabetes
Iris Castro-Revoredo1, Sara C Markley Webster2
1Division of General Medicine, Emory University School of Medicine, Faculty Office Building, Suite 486, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303, USA.
The Medical Clinics of North America
|April 26, 2026
Summary
This review covers noninsulin medications for type 2 diabetes, detailing mechanisms, efficacy, and safety. It emphasizes a patient-centered approach, guiding evidence-based therapy selection to improve outcomes and prevent complications.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes management is evolving from glucose-focused to patient-centered care.
- Selecting appropriate noninsulin pharmacotherapy is crucial for improving patient outcomes.
- Comorbidity prevention is a key goal in contemporary diabetes treatment.
Purpose of the Study:
- To review current noninsulin medication classes for type 2 diabetes.
- To detail the mechanism of action, efficacy, and safety profiles of these agents.
- To discuss clinical considerations for evidence-based therapy selection.
Main Methods:
- Comprehensive literature review of noninsulin antidiabetic agents.
- Analysis of pharmacological mechanisms, clinical trial data, and safety profiles.
- Synthesis of information for clinical application and patient-centered decision-making.
Main Results:
- Detailed overview of major noninsulin drug classes: biguanides, insulin secretagogues, thiazolidinediones, alpha-glucosidase inhibitors, SGLT2 inhibitors, DPP4 inhibitors, GLP1 receptor agonists, dual GLP1/GIP receptor agonists, and amylin analogs.
- Discussion of efficacy, safety, and specific indications for each class.
- Highlighting the shift towards personalized, evidence-based treatment strategies.
Conclusions:
- Noninsulin medications offer diverse mechanisms to manage type 2 diabetes effectively.
- A patient-centered, evidence-based approach is essential for optimizing treatment and preventing comorbidities.
- Understanding the nuances of each drug class facilitates improved clinical decision-making and patient outcomes.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
990
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:22Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K